| 3/31/2017 | BKCV | Moody’s rates TiVo Ba3, stable
|
| 1/18/2017 | BKCV | S&P lifts Rovi, rates TiVo BB-
|
| 9/8/2016 | CV | TiVo, Rovi revise conversion rights for convertible notes after merger
|
| 5/3/2016 | BKCV | S&P: Rovi on positive watch
|
| 4/29/2016 | CV | Market Commentary: New Knowles adds on swap; Molina drops outright, adds on swap; TiVo, Pandora improve
|
| 4/29/2016 | CV | Market Commentary: Morning Commentary: New, upsized Knowles adds on swap; TiVo bonds gain on Rovi takeover
|
| 4/1/2016 | CV | Market Commentary: Anacor up slightly on outright basis; new Gran Tierra adds; Rovi expands dollar neutral
|
| 3/11/2016 | BKCV | S&P upgrades Rovi to BB
|
| 10/30/2015 | CV | Market Commentary: Integrated Device Technology adds outright on debut; Allergan active, trades in line
|
| 10/30/2015 | CV | Market Commentary: Morning Commentary: New Integrated Device Technology adds on debut; Allergan trades in line
|
| 10/29/2015 | CV | Market Commentary: Allergan mandatory edges higher on news of deal talks; Peabody sinks to new lows; NXP, Rovi shares drop
|
| 10/29/2015 | CV | Market Commentary: Morning Commentary: Allergan mandatory edges higher on deal talks; Rovi drops after missing estimates
|
| 4/2/2015 | CV | Market Commentary: New Trinity Biotech quiet, shares lower; overall market muted ahead of holiday weekend
|
| 3/24/2015 | BKCV | Moody's upgrades Rovi loans
|
| 3/4/2015 | CV | Rovi greenshoe exercise ups 0.5% convertibles to $345 million
|
| 3/2/2015 | CV | Market Commentary: NXP Semiconductors expands after merger news; American Realty improves; Gogo to price
|
| 2/27/2015 | CV | Market Commentary: New Rovi bond jumps outright, adds dollar neutral; Goodrich Petroleum pops; EnerNOC tanks
|
| 2/27/2015 | CV | Market Commentary: Morning Commentary: New Rovi bond bid higher with better shares; Goodrich Petroleum pops
|
| 2/27/2015 | CV | New Issue: Rovi sells $300 million five-year convertibles to yield 0.5%, up 26%
|
| 2/26/2015 | CV | Market Commentary: American Tower mandatory adds on debut; Prologis expands on hedge; salesforce contracts
|
| 2/25/2015 | CV | Rovi plans $300 million five-year convertibles to yield 0.25%-0.75%, up 22.5%-27.5%
|
| 6/12/2014 | BKCV | Moody’s gives Rovi facilities Ba3
|
| 6/12/2014 | BKCV | S&P rates Rovi loan BB-
|
| 11/14/2013 | BKCV | Moody's: Rovi view to negative
|
| 9/25/2013 | BKCV | S&P downgrades Rovi
|
| 3/28/2013 | BKCV | Moody's: Rovi loan amendment is credit positive
|
| 1/23/2013 | CV | Market Commentary: Planned KB Home adds in gray; newer Theravance still weak; Molycorp, OPKO, Auxilium on tap
|
| 8/10/2012 | CV | Market Commentary: MGM better on outright demand; Janus adds on investment stake; Hornbeck trades up, in line
|
| 7/23/2012 | BKCV | Moody's: Rovi unchanged
|
| 7/18/2012 | CV | Market Commentary: Rovi mixed on profit warning; EMC active on earnings; no recovery for FiberTower holders
|
| 5/4/2012 | CV | Market Commentary: Rovi bounces back after early stumble; SandRidge quiet after earnings; Chesapeake steadies
|
| 3/13/2012 | BKCV | Moody's cuts Rovi loan to Ba2, rates new loans Ba2
|
| 11/11/2011 | CV | Market Commentary: Convertible bid strengthens, but quietly on holiday; Take-Two expands slightly dollar neutral
|
| 11/10/2011 | CV | Market Commentary: Take-Two's planned $200 million deal in focus ahead of pricing; Regeneron trades at 92.75
|
| 11/9/2011 | CV | Market Commentary: Rovi gains dollar neutral as dour outlook torpedoes stock; Salix adds outright; GM lower
|
| 5/11/2011 | CV | Market Commentary: PDL BioPharma up outright, flat on swap on debut; Rovi adds dollar neutral as stock surges
|
| 1/25/2011 | BKCVHY | Moody's rates Rovi loans Ba1
|
| 1/25/2011 | BKCVHY | S&P rates Rovi loans BB+
|
| 1/6/2011 | BKCVHY | S&P: Rovi outlook stable
|
| 12/23/2010 | CV | Market Commentary: Convertibles quiet; Navistar sees low print after earnings; Medtronic firmer; GM flat
|
| 12/23/2010 | CVLM | Rovi intends to repurchase up to $200 million convertible notes
|
| 6/4/2010 | CV | Short-dated convertibles may offer optionality, limited downside in volatile market: Citi
|
| 4/1/2010 | CV | Market Commentary: Corporate Office slips on debut; Micron trades up in line after earnings; Medtronic active
|
| 3/19/2010 | CV | Market Commentary: Hartford eases with stock; Lifepoint, other health care names steady to stronger; Rovi slips
|
| 3/17/2010 | CV | Rovi greenshoe on its 2.625% convertibles lifts deal to $460 million
|
| 3/12/2010 | CV | Market Commentary: New Rovi adds on debut; week's new issuance totals reach $1.62 billion; Ford, Hologic up
|
| 3/12/2010 | CV | New Issue: Rovi prices $400 million 30-year convertibles to yield 2.625%, up 28%
|
| 3/11/2010 | CV | Market Commentary: International Coal trades up on debut; Hologic higher in active trade; Smithfield active
|
| 3/10/2010 | BKCVHY | S&P: Rovi outlook positive
|
| 3/10/2010 | BKCVHY | Moody's ups Rovi loans to Baa3
|
| 3/10/2010 | CV | Market Commentary: ProLogis trades actively; Ciena extends gains; Health Care REIT, International Coal price
|
| 3/10/2010 | CV | Rovi plans to price $400 million 30-year convertible notes to yield 2.5%-3%, up 25%-30%
|
